{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T13:17:04Z","timestamp":1775222224960,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T00:00:00Z","timestamp":1535500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T00:00:00Z","timestamp":1535500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Renal insufficiency is common in patients with relapsed multiple myeloma and can often limit choice of therapy. Lenalidomide, a critical agent in the treatment of relapsed multiple myeloma, is renally cleared., This phase I\/II trial evaluated the efficacy and safety of lenalidomide with dexamethasone in patients with relapsed multiple myeloma and renal insufficiency. Three groups were treated, with creatinine clearance 30\u201360\u2009cc\/hr (group A), CrCl\u2009&lt;\u200930 not on dialysis (group B), and patients on dialysis (group C) at escalating doses of lenalidomide. A total of 63 patients were treated and no DLTs were observed in phase I. All three groups were able to escalate to full dose lenalidomide 25\u2009mg daily 21\/28 days, although due to reduced accrual the phase II component was not entirely completed for groups B and C. Adverse events were as expected, including anemia, diarrhea and fatigue. Ten patients experienced grade 3\u20134 pneumonia. Overall response rate was 54% across all groups. PFS was 7.5 months and OS was 19.7 months. Lenalidomide can be given at full dose 25\u2009mg daily 21\/28 in patients with a CrCl\u2009&gt;\u200930, and can be given daily to those with CrCl\u2009&lt;\u200930, even when on dialysis, at doses of at least 15\u2009mg daily.<\/jats:p>","DOI":"10.1038\/s41408-018-0110-7","type":"journal-article","created":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T17:03:28Z","timestamp":1535562208000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study"],"prefix":"10.1038","volume":"8","author":[{"given":"Joseph","family":"Mikhael","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Manola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amylou C.","family":"Dueck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Hayman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt","family":"Oettel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham S.","family":"Kanate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,29]]},"reference":[{"key":"110_CR1","unstructured":"SEER Cancer Statistics Factsheets: myeloma. National Cancer Institute: Bethesda, MD [cited 24 January 2018]. Available from http:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"key":"110_CR2","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/ajh.24392","volume":"91","author":"V Rajkumar","year":"2016","unstructured":"Rajkumar, V. Myeloma today: disease definitions and treatment advances. Am. J. Hematol. 91, 965 (2016).","journal-title":"Am. J. Hematol."},{"key":"110_CR3","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1200\/JCO.2016.71.1663","volume":"35","author":"CHY van Beurden-Tan","year":"2017","unstructured":"van Beurden-Tan, C. H. Y. et al. Systematic literature review and network meta-analysis of treatment outcomes in relapsed and\/or refractory multiple myeloma. J. Clin. Oncol. 35, 1312\u20131319 (2017).","journal-title":"J. Clin. Oncol."},{"key":"110_CR4","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/kisup.2013.79","volume":"3","author":"R Kazancioglu","year":"2013","unstructured":"Kazancioglu, R. Risk factors for chronic kidney disease: an update. Kidney Int Suppl. (2011) 3, 368\u2013371 (2013).","journal-title":"Kidney Int Suppl. (2011)"},{"key":"110_CR5","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/j.1365-2141.2007.06698.x","volume":"138","author":"R Niesvizky","year":"2007","unstructured":"Niesvizky, R. et al. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naive patients undergoing front-line lenalidomide and dexamethasone therapy. Br. J. Haematol. 138, 640\u2013643 (2007).","journal-title":"Br. J. Haematol."},{"key":"110_CR6","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1177\/0091270007309563","volume":"47","author":"N Chen","year":"2007","unstructured":"Chen, N. et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J. Clin. Pharmacol. 47, 1466\u20131475 (2007).","journal-title":"J. Clin. Pharmacol."},{"key":"110_CR7","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/0277-5379(91)90020-E","volume":"27","author":"A Riccardi","year":"1991","unstructured":"Riccardi, A. et al. Changing clinical presentation of multiple myeloma. Eur. J. Cancer 27, 1401\u20131405 (1991).","journal-title":"Eur. J. Cancer"},{"key":"110_CR8","first-page":"207","volume":"56","author":"KC Abbott","year":"2001","unstructured":"Abbott, K. C. & Agodoa, L. Y. Multiple myeloma and light chain-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival. Clin. Nephrol. 56, 207\u2013210 (2001).","journal-title":"Clin. Nephrol."},{"key":"110_CR9","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1093\/ndt\/gfp679","volume":"25","author":"DJ Tsakiris","year":"2010","unstructured":"Tsakiris, D. J. et al. Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study. Nephrol. Dial. Transplant. 25, 1200\u20131206 (2010).","journal-title":"Nephrol. Dial. Transplant."},{"key":"110_CR10","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1053\/j.ajkd.2011.12.028","volume":"59","author":"SH Nasr","year":"2012","unstructured":"Nasr, S. H. et al. Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies. Am. J. Kidney Dis. 59, 786\u2013794 (2012).","journal-title":"Am. J. Kidney Dis."},{"key":"110_CR11","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa070596","volume":"357","author":"DM Weber","year":"2007","unstructured":"Weber, D. M. et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N. Engl. J. Med. 357, 2133\u20132142 (2007).","journal-title":"N. Engl. J. Med."},{"key":"110_CR12","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa070594","volume":"357","author":"M Dimopoulos","year":"2007","unstructured":"Dimopoulos, M. et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N. Engl. J. Med. 357, 2123\u20132132 (2007).","journal-title":"N. Engl. J. Med."},{"key":"110_CR13","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart, A. K. et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 372, 142\u2013152 (2015).","journal-title":"N. Engl. J. Med."},{"key":"110_CR14","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau, P. et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 374, 1621\u20131634 (2016).","journal-title":"N. Engl. J. Med."},{"key":"110_CR15","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos, M. A. et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 375, 1319\u20131331 (2016).","journal-title":"N. Engl. J. Med."},{"key":"110_CR16","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial, S. et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N. Engl. J. Med. 373, 621\u2013631 (2015).","journal-title":"N. Engl. J. Med."},{"key":"110_CR17","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1365-2141.2010.08250.x","volume":"150","author":"SA Schey","year":"2010","unstructured":"Schey, S. A. et al. The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed\/refractory myeloma patients; a phase I\/II study. Br. J. Haematol. 150, 326\u2013333 (2010).","journal-title":"Br. J. Haematol."},{"key":"110_CR18","doi-asserted-by":"publisher","first-page":"4608","DOI":"10.1182\/blood-2011-12-395715","volume":"119","author":"S Lentzsch","year":"2012","unstructured":"Lentzsch, S. et al. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1\/2 open-label, dose escalation study. Blood 119, 4608\u20134613 (2012).","journal-title":"Blood"},{"key":"110_CR19","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1002\/cncr.25139","volume":"116","author":"M Dimopoulos","year":"2010","unstructured":"Dimopoulos, M. et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and\/or refractory multiple myeloma patients with impaired renal function. Cancer 116, 3807\u20133814 (2010).","journal-title":"Cancer"},{"key":"110_CR20","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/j.1600-0609.2010.01500.x","volume":"85","author":"J de la Rubia","year":"2010","unstructured":"de la Rubia, J. et al. Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study. Eur. J. Haematol. 85, 363\u2013365 (2010).","journal-title":"Eur. J. Haematol."},{"key":"110_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0609.2010.01461.x","volume":"85","author":"MA Dimopoulos","year":"2010","unstructured":"Dimopoulos, M. A. et al. Lenalidomide and dexamethasone for the treatment of refractory\/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. Eur. J. Haematol. 85, 1\u20135 (2010).","journal-title":"Eur. J. Haematol."},{"key":"110_CR22","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00277-010-1080-4","volume":"90","author":"U Klein","year":"2011","unstructured":"Klein, U. et al. Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment. Ann. Hematol. 90, 429\u2013439 (2011).","journal-title":"Ann. Hematol."},{"key":"110_CR23","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s12185-015-1771-7","volume":"101","author":"DB Zhou","year":"2015","unstructured":"Zhou, D. B. et al. Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment. Int. J. Hematol. 101, 569\u2013577 (2015).","journal-title":"Int. J. Hematol."},{"key":"110_CR24","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","volume":"34","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos, M. A. et al. International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment. J. Clin. Oncol. 34, 1544\u20131557 (2016).","journal-title":"J. Clin. Oncol."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0110-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0110-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0110-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T11:36:59Z","timestamp":1671536219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0110-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,29]]},"references-count":24,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,9]]}},"alternative-id":["110"],"URL":"https:\/\/doi.org\/10.1038\/s41408-018-0110-7","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,29]]},"assertion":[{"value":"19 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Mikhael\u2014research funding from Abbvie, Celgene, and Sanofi","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"86"}}